• Regenxbio plans an underwritten public offering of USD 100 million of common stock, subject to market conditions.
• Underwriters will receive a 30-day option to buy up to 15% more shares than the base deal size.
• Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho will act as joint book-running managers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607161626PR_NEWS_USPR_____PH06643) on July 16, 2026, and is solely responsible for the information contained therein.